Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.
Clinical Scorecard: Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
At a Glance
Category Detail
Condition Locally Advanced Unresectable Pancreatic Cancer Key Mechanisms Adaptive Radiation Therapy (ART) aims to improve targeting of aggressive cancer cells while protecting healthy tissue. Target Population Patients with histologically or cytologically-confirmed locally advanced unresectable pancreatic ductal adenocarcinoma (PDA). Care Setting Clinical trial setting for cancer treatment.
Key Highlights
Participants receive 5 radiation treatments every other day over a 2-week period. Inclusion criteria include ECOG performance status 0-2 and adequate organ function. Participants must have unresectable disease confirmed by a multidisciplinary conference. Guideline-Based Recommendations
Diagnosis
Histologically or cytologically-confirmed PDA is required. Management
Patients must be reviewed by a pancreatic surgeon and assessed by medical oncology for induction chemotherapy eligibility. Monitoring & Follow-up
Blood samples are collected before, during, and after radiation treatment. Risks
Exclusion of patients with prior radiation therapy for pancreatic cancer or confirmed metastatic disease. Patient & Prescribing Data
Adults aged 18 years and older with locally advanced unresectable PDA.
Patients must not have had chemotherapy within 2 weeks prior to starting ART.
Clinical Best Practices
Ensure informed consent and HIPAA consent are signed prior to study procedures. Monitor for adverse events and ensure recovery to < Grade 2 before treatment initiation. Related Resources & Content
